Table 3 Determinants of TLR among cases

Pathology:

=0.158#

 IDC(n=36)

3.96±3.10

2.85(3.4)

 ILC

2.41±2.98

0.80(5.3)

 Others

1

Menopausal State

 Pre- (n=19)

5.27±3.55

4.7 (5.1)

= 0.002*

 Post- (n=21)

2.41± 1.72

1.88 (2)

Disease stage

 I & II (n=27)

3.21±2.28

2.32(3.37)

= 0.039**

 III & IV (n=13)

4.93±4.15

2.9(6.36)

ER-Receptors

 Positive (n=31)

3.12 ±2.32

2.5 (2.97)

= 0.095**

 Negative (n=9)

5.99±4.62

4.7 (7.6)

PR-Receptors

 Positive (n=24)

3.12±2.32

2.56 (3.39)

= 0.129**

 Negative (n=16)

4.74±3.81

3.25 (6.25)

Her2 neu -Receptors

 Positive (n=14)

4.26±2.46

4 (4.23)

= 0.0476*

 Negative (n=26)

3.51±3.37

2.17 (2.68)

Axillary LN Stat

 Positive (n=27)

4.58±3.39

3.52 (5.54)

= 0.022**

 Negative(n=13)

2.10±1.26

1.86 (1.96)

Tumor grade

• GI (n=5)

• GII (n=18)

• GIII (n=15)

GI (n=5)

1.35±0.6

1.16 (1.13)

= 0.005#

GII (n=18)

3.21±2.26

2.38 (3.35)

GIII (n=15)

5.42±3.38

3.31± (6)

Molecular subtype

• Luminal A (n=10)

• Luminal B (n=19)

• Her2neuover expression (n=4)

• Basal Like (n=7)

(triple negative)

Luminal A (n=10)

1.96±1.6

1.45 (1.77)

= 0.018#

Luminal B (n=19)

• Luminal A (n=10)

• Luminal B (n=19)

• Her2neuover expression (n=4)

• Basal Like (n=7)

(triple negative)

3.85±2.27

3 (3.66)

Her2neu-overexpression expression (n=4)

2.57±1.74

2.26 (3.25)

Triple negative (n=7)

6.9±4.82

8.12(8.29)